EPO mimetic peptides were designed to stimulate non-erythroid EPO-like activity without increasing hematocrit such as ARA290 that has been suggested to benefit human metabolic control and neuropathy69–71, raising the potential for EPO mimetics to treat obesity and metabolic syndromes. Here, EPO is linked to obesity due to melanocortin 4 receptor deficiency.